tiprankstipranks
Trending News
More News >

Recursion Pharmaceuticals price target lowered to $5 from $8 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $5 from $8 and keeps an Equal Weight rating on the shares. The firm revised its model following the company’s recent pipeline prioritizations, cost reductions, 20% workforce reduction and updated cash burn guidance.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

1